Abstract |
A case with WDHA syndrome due to VIPoma is reported. Injection of somatostatin analogue SMS 201-995 was followed by prompt suppression of vasoactive intestinal polypeptide levels (VIP), decreased stool volume, and restoration of the serum potassium concentration to normal. Long-term treatment with SMS 201-995 for up to 20 weeks produced excellent clinical control and a decrease in tumour size. No adverse effects were noted except for localized pain at the site of injection. This was overcome by using a continuous subcutaneous infusion pump which also enabled the effective daily dosage to be reduced and thereby adverse reactions to be avoided.
|
Authors | Y Niitsu, Y Goto, M Maeda, N Tsushima, N Watanabe, Y Kohgo, I Urushizaki |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 2
Issue 3
Pg. 269-79
(Jun 1988)
ISSN: 0269-2813 [Print] England |
PMID | 2856504
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
|
Topics |
- Female
- Humans
- Infusions, Intravenous
- Middle Aged
- Octreotide
(administration & dosage, therapeutic use)
- Pancreatic Neoplasms
(drug therapy)
- Vipoma
(drug therapy)
|